Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer
| Autor: | Mario Scartozzi, Francesco Cabras, Francesco Scintu, Giuseppe Casula, Ivana Maria Francesca Cocco, Luigi Zorcolo, Angelo Restivo |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Oncology Cancer Research medicine.medical_specialty Colorectal cancer medicine.medical_treatment Antineoplastic Agents Lower risk Preoperative care Gastroenterology Disease-Free Survival Breast cancer Internal medicine Preoperative Care Humans Medicine rectal cancer Neoadjuvant therapy Aged Aspirin Rectal Neoplasms business.industry Hazard ratio Chemoradiotherapy Middle Aged Prognosis medicine.disease Neoadjuvant Therapy Chemotherapy Adjuvant Clinical Study Female business medicine.drug |
| Zdroj: | British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1038/bjc.2015.336 |
| Popis: | Background: Recently, many studies have suggested a possible adjuvant role of aspirin in colorectal cancer, reporting a positive prognostic effect with its use in patients with established disease. The aim of this study was to investigate the anticancer effect of aspirin use during preoperative chemoradiation for rectal cancer. Methods: Two hundred and forty-one patients with stage II–III rectal cancer and candidates for chemoradiation (CRT) were selected and assigned to two groups: group 1, patients taking aspirin at the time of diagnosis, and group 2, all others. Treatment and oncological outcomes were explored. Results: Aspirin use was associated with a higher rate of tumour downstaging (67.6% vs 43.6%, P=0.01), good pathological response (46% vs 19% P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|